Cargando…

OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides

This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Berman, Cindy L., Antonsson, Madeleine, Batkai, Sandor, Bosgra, Sieto, Chopda, Girish R., Driessen, Wouter, Foy, Jeffrey, Hassan, Chopie, Hu, Xiao Shelley, Jang, Hyun Gyung, Meena,  , Sanseverino, Mark, Thum, Thomas, Wang, Yanfeng, Wild, Martin, Wu, Jing-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561745/
https://www.ncbi.nlm.nih.gov/pubmed/37590469
http://dx.doi.org/10.1089/nat.2023.0011
Descripción
Sumario:This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinical studies. In general, the recommended approach is similar to that for small molecule drugs. However, some differences in timing and/or scope may be warranted due to the greater consistency of results across ON classes as compared with the diversity among small molecule classes. For some types of studies, a platform-based approach may be appropriate; once sufficient data are available for the platform, presentation of these data should be sufficient to support development of additional ONs of the same platform. These recommendations can serve as a starting point for nonclinical study design and foundation for discussions with regulatory agencies.